Lipiodol Ultra Fluide
ApprovedSmall molecule
Lipiodol Ultra Fluide is one of 13 small molecule programs targeting Flushing. It is currently in Approved.
1
Indications
1
Total Trials
1
Active Trials
12
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
24 competitors in Flushing
#DrugCompanyPhaseTrials
1Xylocaine
MMEDRx USA, Inc.
Approved
Niacor
AbbViePhase 3
Botulinum Toxin a
GSKApproved
Hcg
Changchun GeneScience Pharmaceutical Co., Ltd.Approved
Heparin Sodium
BBaxter Healthcare Corporation
Phase 3
BG00012
BiogenPhase 3
Nitrostat
VViatris Specialty LLC
Phase 2
Lipiodol Ultra Fluide
DDafne Balemans
Approved
Alphagan
AbbViePhase 1
Bayer Aspirin
BayerPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Lipiodol Ultra Fluide. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- DDafne Balemans